GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Roche Holding AG (OTCPK:RHHBY) » Definitions » EPS (Diluted)

Roche Holding AG (Roche Holding AG) EPS (Diluted)

: $2.02 (TTM As of Dec. 2023)
View and export this data going back to 2002. Start your Free Trial

Roche Holding AG's Earnings per Share (Diluted) for the six months ended in Dec. 2023 was $0.79. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $2.02.

Roche Holding AG's EPS (Basic) for the six months ended in Dec. 2023 was $0.79. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $2.03.

Roche Holding AG's EPS without NRI for the six months ended in Dec. 2023 was $1.22. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $2.63.

During the past 12 months, Roche Holding AG's average EPS without NRIGrowth Rate was -8.50% per year. During the past 3 years, the average EPS without NRIGrowth Rate was -1.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was 0.50% per year. During the past 10 years, the average EPS without NRI Growth Rate was 4.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Roche Holding AG's highest 3-Year average EPS without NRI Growth Rate was 31.30% per year. The lowest was -29.40% per year. And the median was 5.60% per year.


Roche Holding AG EPS (Diluted) Historical Data

The historical data trend for Roche Holding AG's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roche Holding AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.99 2.32 2.20 2.06 2.07

Roche Holding AG Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EPS (Diluted) Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.97 1.36 0.65 1.23 0.79

Competitive Comparison

For the Drug Manufacturers - General subindustry, Roche Holding AG's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Roche Holding AG PE Ratio Distribution

For the Drug Manufacturers industry and Healthcare sector, Roche Holding AG's PE Ratio distribution charts can be found below:

* The bar in red indicates where Roche Holding AG's PE Ratio falls into.



Roche Holding AG EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Roche Holding AG's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(13295.56-0)/6432.000
=2.07

Roche Holding AG's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(5042.784-0)/6432.000
=0.78

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $2.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Roche Holding AG  (OTCPK:RHHBY) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Roche Holding AG EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Roche Holding AG's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Roche Holding AG (Roche Holding AG) Business Description

Address
Grenzacherstrasse 124, Basel, CHE, 4070
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's best-selling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Roche Holding AG (Roche Holding AG) Headlines

From GuruFocus

Analysts Tab Veeva Systems as a Top Value Pick

By Barry Cohen 05-25-2022